The Lancet. HaematologyAdultAged80 and overFemaleHumans
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.
Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti, API-CAT Study Group, API-CAT Investigators
Published: 202610.1016/S2352-3026(25)00291-1
Abstract
BACKGROUND: Extended anticoagulation with reduced-dose apixaban was shown to be non-inferior to full-dose apixaban for preventing recurrent venous thromboembolism (VTE) in patients with active cancer and to be associated with fewer clinically relevan…
Preview only. Read the full abstract at the source